Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

ArriVent BioPharma, Inc. (AVBP) stock profile

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines to address unmet medical needs in cancer patients. The company specializes in developing and commercializing targeted cancer therapies for non-small-cell lung cancer and other solid tumors. Its lead development candidate is furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor currently undergoing Phase 3 clinical trials for the treatment of non-small-cell lung cancer patients. The company also develops ARR-002 and maintains strategic collaborations with Aarvik Therapeutics Inc. ArriVent BioPharma was incorporated in 2021 and is headquartered in Newtown Square, Pennsylvania.

Key facts

SymbolAVBP
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOZhengbin Yao
Employees77
HeadquartersNewtown Square, PA, US
IPO2024-01-26
Websitearrivent.com

Explore AVBP on Vantafin

  • ArriVent BioPharma, Inc. Overview
  • ArriVent BioPharma, Inc. Financials
  • ArriVent BioPharma, Inc. News
  • ArriVent BioPharma, Inc. Events
  • ArriVent BioPharma, Inc. SEC filings
  • ArriVent BioPharma, Inc. Insider transactions

Frequently asked questions

What does ArriVent BioPharma, Inc. (AVBP) do?
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines to address unmet medical needs in cancer patients. The company specializes in developing and commercializing targeted cancer therapies for non-small-cell lung cancer and other solid tumors. Its lead development candidate is furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor currently undergoing Phase 3 clinical trials for the treatment of non-small-cell lung cancer patients. The company also develops ARR-002 and maintains strategic collaborations with Aarvik Therapeutics Inc. ArriVent BioPharma was incorporated in 2021 and is headquartered in Newtown Square, Pennsylvania.
Where is AVBP stock listed?
ArriVent BioPharma, Inc. trades under the ticker AVBP on NASDAQ.
How can I research AVBP's financials and filings?
Vantafin provides ArriVent BioPharma, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the AVBP profile.